NeuroScientific Biopharmaceuticals Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

May 25

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Jan 27

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Oct 07

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Jun 23

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Mar 10

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Nov 18

AMMINISTRATORE DELEGATO

NeuroScientific Biopharmaceuticals non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Anthony Keating	Executive Director	less than a year	AU$158.83k	Nessun dato
Frank Bonner	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Peter Hnik	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Christopher Ntoumenopoulos	Non-Executive Chairman of the Board	less than a year	AU$53.43k	Nessun dato
Anton Uvarov	Non-Executive Director	7.2yrs	AU$51.77k	1.63% A$ 87.0k
Dao-Yi Yu	Member of Scientific Advisory Board	4.3yrs	Nessun dato	Nessun dato
Allan Kermode	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
Clarke Barlow	Non-Executive Director	less than a year	AU$33.80k	Nessun dato

3.3yrs

Durata media

55.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NSB sono considerati esperti (durata media dell'incarico 3.3 anni).

NeuroScientific Biopharmaceuticals Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 06, 2024

NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors

NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023

Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023

Neuroscientific Biopharmaceuticals Limited Announces Board Changes

NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director

Recent updates

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 06, 2024

NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors

NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023

Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023

Neuroscientific Biopharmaceuticals Limited Announces Board Changes

NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 23, 2023

Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes

NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"

NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO

Less than half of directors are independent

NeuroScientific Biopharmaceuticals Limited Announces Management Changes

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director

Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial

NeuroScientific Biopharmaceuticals Limited Announces Human Research Ethics Committee Submission for Phase I Clinical Trial

NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial

NeuroScientific Biopharmaceuticals Limited Announces Clarification of Results in Ms Animal Study

NeuroScientific Biopharmaceuticals Limited Announces Positive Preliminary Results of Lead Drug Candidate EMTINB

Neuroscientific Biopharmaceuticals Ltd Receives Approval from the Human Research Ethics Committee for its Early-Phase Clinical Trial of Lead Drug Candidate EmtinBTM

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

Neuroscientific Biopharmaceuticals Limited Announces Submission for HREC Approval of Early-Phase Clinical Trial of EmtinBTM

Less than half of directors are independent

NeuroScientific Biopharmaceuticals Limited Announces Positive Safety Result Supports Advance to Clinical Trials

NeuroScientific Biopharmaceuticals Limited Announces Management Appointments

NeuroScientific Biopharmaceuticals Limited Successful Completion of Key Studies in Lead Up to Phase I Clinical Studies

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Neuroscientific Biopharmaceuticals Limited Announces Positive Off-Target Safety Assessment of Emtinb

Neuroscientific Biopharmaceuticals Limited Announces Positive Results in Biomarker Characterisation of Emtins

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Non-Executive Chairman recently bought AU$100k worth of stock

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Non-Executive Chairman Brian Leedman has left the company

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

New 90-day low: AU$0.21

Non-Executive Chairman exercised options to buy AU$69k worth of stock.

New 90-day low: AU$0.23

New 90-day low: AU$0.24

Neuroscientific Biopharmaceuticals Limited Initiates A New Preclinical Program in Partnership with the Institute of Respiratory Health and the University of Western Australia

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

New 90-day high: AU$0.35

New 90-day high: AU$0.32

New 90-day high: AU$0.27

New 90-day high - AU$0.24

New 90-day high - AU$0.24

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media